Caplin Point Arm Receives USFDA Form 483

CHENNAI — Pharmaceutical manufacturer Caplin Point Laboratories Limited announced on Thursday, August 21, 2026, that its subsidiary, Caplin Steriles Limited, has received a Form 483 containing 10 observations from the United States Food and Drug Administration (USFDA).

The unannounced audit evaluated the company's specialized injectable and ophthalmic manufacturing facility located in Gummidipoondi, Tamil Nadu. The inspection, conducted between August 13 and August 21, 2026, concluded with management confirming that all noted items are procedural in nature, with zero repeat observations and no data integrity concerns raised.

Audit Findings and Corrective Action Plan

Form 483 observations are issued by USFDA investigators to highlight conditions or practices that may require administrative or technical adjustments to meet current good manufacturing practices (cGMP). Company executives noted that the technical and quality assurance teams have initiated a comprehensive review to address each observation thoroughly within the statutory timeframe.

According to official stock exchange filings, corporate disclosures, and regulatory notifications:

• Facility Audited: Caplin Steriles Limited manufacturing plant in Gummidipoondi, Tamil Nadu.

• Audit Dates: Conducted from August 13 to August 21, 2026.

• Regulatory Outcome: USFDA issued a Form 483 with 10 observations.

• Compliance Status: Management confirmed that none of the findings involve data integrity issues or represent repeat observations from previous audits.

Official Sources Section

• National Stock Exchange of India (NSE) Corporate Filings: Official material event disclosures, stock exchange intimation notices, and regulatory filings submitted by Caplin Point Laboratories.

• BSE India Corporate Disclosures: Exchange compliance archives and regulatory filing records.

• U.S. Food and Drug Administration (USFDA): Regulatory inspection guidelines, cGMP standards, and compliance documentation.

Quote Section

According to statements released in official stock exchange filings by Caplin Point Laboratories regarding the inspection:

"The observations are procedural in nature and do not pertain to data integrity, and none of them were repeat observations. The Company is addressing the observations comprehensively and will respond to the US FDA within the stipulated timeframe."

— Venkatram G., General Counsel & Company Secretary

Why It Matters

For institutional investors, healthcare analysts, and international pharmaceutical partners, maintaining regulatory compliance at sterile injectable facilities is vital for export continuity. Prompt remediation of procedural observations ensures that pending and future product approvals in the United States market proceed without administrative delays.

Key Facts at a Glance

• Company: Caplin Point Laboratories Limited (Subsidiary: Caplin Steriles Limited).

• Facility Location: Gummidipoondi, Tamil Nadu.

• Regulatory Body: United States Food and Drug Administration (USFDA).

• Outcome: Form 483 issued with 10 procedural observations.

FAQ Section

What is the significance of the USFDA inspection at Caplin Steriles?

The USFDA conducted an unannounced routine audit of the injectable and ophthalmic manufacturing facility in Gummidipoondi, concluding with a Form 483 containing 10 observations.

Do the observations involve data integrity issues?

No. Company management explicitly stated that the observations are procedural in nature, with zero repeat findings and no concerns regarding data integrity.

Does this inspection result in a product ban or plant shutdown?

A Form 483 lists inspectional observations requiring a formal response and Corrective and Preventive Action (CAPA) plan, but it does not represent a final regulatory penalty or a suspension of operations.

Where can investors review the official exchange disclosures?

Official material event notifications and regulatory filings are published directly on the BSE and NSE corporate announcement portals.

Source: NSE India, BSE India, USFDA, Caplin Point Laboratories